<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186082</url>
  </required_header>
  <id_info>
    <org_study_id>95339</org_study_id>
    <nct_id>NCT00186082</nct_id>
  </id_info>
  <brief_title>Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs</brief_title>
  <official_title>A Randomized Controlled Trial of the Effect of Prophylactic Antibiotics on the Infection Rate in Postpartum Third and Fourth Degree Perineal Tear Repairs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Santa Clara Valley Health &amp; Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is undertaken to find out whether prophylactic antibiotics can decrease the
      infection rate in third and fourth degree perineal tear repairs done in the immediate
      postpartum period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After obtaining consent patients who sustained third or fourth degree perineal laceration
      after vaginal delivery were randomly assigned to a single dose of antibiotic (cefotetan or
      cefoxitin, 1 g intravenously or clindamycin, 900 mg intravenously, if allergic to
      penicillin), or placebo (100ml normal saline) intravenously.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No perineal breakdown or infection</measure>
    <time_frame>Six weeks post partum</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Pregnancy Complications, Infectious</condition>
  <arm_group>
    <arm_group_label>Cefotetan, Cefoxitin or Clindamycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefotetan or Cefoxitin vs placebo</intervention_name>
    <description>Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.
Normal Saline, 100 ml intravenously for placebo arm.</description>
    <arm_group_label>Cefotetan, Cefoxitin or Clindamycin</arm_group_label>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - third and fourth degree perineal laceration

        Exclusion Criteria:

        - chorioamnionitis, HIV positive, inflammatory bowel disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yasser Yehia El-Sayed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Duggal N, Mercado C, Daniels K, Bujor A, Caughey AB, El-Sayed YY. Antibiotic prophylaxis for prevention of postpartum perineal wound complications: a randomized controlled trial. Obstet Gynecol. 2008 Jun;111(6):1268-73. doi: 10.1097/AOG.0b013e31816de8ad.</citation>
    <PMID>18515507</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>June 13, 2011</last_update_submitted>
  <last_update_submitted_qc>June 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yasser Yehia El-Sayed</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Pregnancy Complications, Infectious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefotetan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

